Literature DB >> 19415658

Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment.

Kohji Nagano1, Takashi Shinkawa, Hironori Mutoh, Osamu Kondoh, Sayuri Morimoto, Noriyuki Inomata, Motooki Ashihara, Nobuya Ishii, Yuko Aoki, Masayuki Haramura.   

Abstract

Here, we report for the first time a comparative phosphoproteomic analysis of distinct tumor cell lines in the presence or absence of the microtubule-interfering agent nocodazole. In total, 1525 phosphorylation sites assigned to 726 phosphoproteins were identified using LC-MS-based technology following phosphopeptide enrichment. Analysis of the amino acid composition surrounding the identified in vivo phosphorylation sites revealed that they could be classified into two motif groups: pSer-Pro and pSer-Asp/Glu. Phosphoproteomic change resulting from nocodazole treatment varied among cell lines in terms of the numbers of total phosphopeptides identified, motif groups, and functional annotation groups; however, the cell lines were equally sensitive to nocodazole. The identified phosphoproteome subset contained major signaling proteins and proteins known to be involved in mitosis, but did not always exhibit the same changes in the tumor cells from nocodazole treatment. In spite of the complex changes observed in the phosphorylation of many of the proteins, possible common features induced by nocodazole were found, including phosphorylation of nucleophosmin (NPM) S254 and coatomer protein complex, subunit alpha (COPA) S173, suggesting that the events are not cell-type specific but events generally occurring in mitosis or induced by a microtubule-interfering agent. Further, temporal analysis of phosphoproteome change revealed that phosphorylation of NPM S254 and COPA S173 was observed from the early (6 h) and late (24 h) time point after nocodazole treatment, respectively, suggesting that NPM S254 may be involved in the induction of M-phase arrest by nocodazole, whereas COPA S173 may be caused as a result of M-phase arrest.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415658     DOI: 10.1002/pmic.200800667

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

1.  Phosphorylation of eIF4GII and 4E-BP1 in response to nocodazole treatment: a reappraisal of translation initiation during mitosis.

Authors:  Mark J Coldwell; Joanne L Cowan; Markete Vlasak; Abbie Mead; Mark Willett; Lisa S Perry; Simon J Morley
Journal:  Cell Cycle       Date:  2013-10-01       Impact factor: 4.534

2.  Mitotic modulation of translation elongation factor 1 leads to hindered tRNA delivery to ribosomes.

Authors:  Gilad Sivan; Ranen Aviner; Orna Elroy-Stein
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

3.  Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.

Authors:  James I Macdonald; Frederick A Dick
Journal:  Genes Cancer       Date:  2012-11

4.  Cdk5 phosphorylation of EFhd2 at S74 affects its calcium binding activity.

Authors:  Edwin Vázquez-Rosa; Eva N Rodríguez-Cruz; Sybelle Serrano; Lucelenie Rodríguez-Laureano; Irving E Vega
Journal:  Protein Sci       Date:  2014-06-18       Impact factor: 6.725

Review 5.  Regulating protein breakdown through proteasome phosphorylation.

Authors:  Jordan J S VerPlank; Alfred L Goldberg
Journal:  Biochem J       Date:  2017-09-24       Impact factor: 3.857

6.  Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4 triggers centriole duplication.

Authors:  Annekatrin Krause; Ingrid Hoffmann
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

7.  Inference and quantification of peptidoforms in large sample cohorts by SWATH-MS.

Authors:  George Rosenberger; Yansheng Liu; Hannes L Röst; Christina Ludwig; Alfonso Buil; Ariel Bensimon; Martin Soste; Tim D Spector; Emmanouil T Dermitzakis; Ben C Collins; Lars Malmström; Ruedi Aebersold
Journal:  Nat Biotechnol       Date:  2017-06-12       Impact factor: 54.908

8.  Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers.

Authors:  Jüri Reimand; Gary D Bader
Journal:  Mol Syst Biol       Date:  2013       Impact factor: 11.429

9.  Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.

Authors:  Xing Guo; Xiaorong Wang; Zhiping Wang; Sourav Banerjee; Jing Yang; Lan Huang; Jack E Dixon
Journal:  Nat Cell Biol       Date:  2015-12-14       Impact factor: 28.824

Review 10.  Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.

Authors:  Haitao Yang; MariaLynn Jaeger; Averi Walker; Daniel Wei; Katie Leiker; Tao Weitao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.